Minims Atropinesulfaat 10 Mg/Ml Oogdruppels, Oplossing (Atropine Sulfate)

Atropine sulfate blocks muscarinic acetylcholine receptors in the iris sphincter and ciliary body. This inhibition prevents parasympathetic contraction, causing the pupil to dilate and the ciliary muscle to relax, which facilitates eye examinations and reduces inflammatory responses.

The prescribed dose of Minims Atropinesulfaat is determined by the treating ophthalmologist based on the specific indication, patient age, and clinical response. The prescriber will provide exact instructions on the number of drops and frequency of administration.

The safety of atropine sulfate eye drops in pregnancy or lactation has not been definitively established. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and under the guidance of a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Atropine sulfate provides a longer duration of pupil dilation and cycloplegia compared with shorter‑acting agents such as tropicamide. This makes it useful when prolonged dilation is needed, but it may also increase the risk of prolonged visual disturbances and requires careful monitoring.

Store the ophthalmic solution at ambient temperature, ideally below 25 °C. Keep the bottle in its original packaging, protect it from direct light and moisture, and ensure the cap is tightly closed to maintain sterility.

The solution is applied topically to the conjunctival sac of the eye. The prescriber will instruct the patient on the number of drops per eye and the frequency, typically using a sterile dropper to avoid contamination.

Serious risks include acute angle‑closure glaucoma, severe allergic reactions such as anaphylaxis, persistent mydriasis, and corneal edema. Patients should be instructed to seek immediate medical attention if they experience severe eye pain, sudden vision loss, or systemic allergic symptoms.

Patients with known hypersensitivity to atropine sulfate or any excipients in the formulation should avoid use. Individuals with narrow‑angle or uncontrolled glaucoma, and those who have had recent ocular surgery that contraindicates dilation, should not receive this medication without specialist advice.